CTIS2024-513207-13-00进行中（未招募）1 期
A randomized phase II trial of Stereotactic Body Radiation Therapy (SBRT) with or without Durvalumab (MEDI4736) in oligometastatic recurrent hormone sensitive prostate cancer patients (POSTCARD - GETUG P13) - POSTCARD - GETUG-P13
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •1.Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening evaluations, 10.Body weight > 30kg, 11.Life expectancy of > 24 months, 12.Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up, 13.Social insurance, 2.Age > or = 18 years at time of study entry, 3.Histologically proven diagnosis of prostate cancer (PCa), 4.PCa patients with a biochemical recurrence Rising PSA” following treatment with curative intent (radical prostatectomy, primary radiotherapy or a combination of both) as defined by the EAU guidelines., 5.Amended A maximum of 5 bone or lymph node metastases diagnosed on Ga-PSMA PET CT, OR a maximum of 3 bone or lymph node metastases diagnosed on FCH-PET CT o= 4 cm for bone metastases o= 2 cm for lymph node metastases, 6.WHO performance state 0-1, 7.Controlled primary tumor. In case the PSA > 0,2 ng/ml in the postoperative setting patients are eligible if a multiparametric MRI or PET scan of the prostate bed rules out a local relapse. Patients after primary radiotherapy should undergo MRI of the prostate according to the European Society of Urogenital Radiology (ESUR) guidelines to rule out local relapse. In case of a suspicious lesion, a biopsy should confirm local recurrence and patients should be referred for local salvage prostatectomy when distant metastases are ruled out. If MRI rules out local relapse, patients are eligible., 8.If ADT has been previously administered to the patient, a minimum of 12 months must have elapsed between the predicted duration of the last injection and inclusion of the patient in the study. For this category of patients, serum testosterone has to be higher than 8.5 nmol/l prior to inclusion., 9.Adequate normal organ and marrow function as defined below: oHaemoglobin =9.0 g/dL oAbsolute neutrophil count (ANC) = 1.5 x 103 /L (= 1500 per mm3) oPlatelet count = 75 x 109/L (=75,000 per mm3) oSerum bilirubin =1.5 x institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of haemolysis or hepatic pathology), who will be allowed only in consultation with their physician. oAST (SGOT)/ALT (SGPT) =2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be =5x ULN oMeasured creatinine clearance (CL) = 40 ml/min or Calculated creatinine CL = 40 ml/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance: Creatinine CL (ml/min)=Weight (kg) x (140 – Age) 72 x serum creatinine (mg/dL)
排除标准
- •1.Serum testosterone level < 8.5 nmol/l, 10.Relapsed primary tumor, 11.Perihilar lymphnode metastases, 12.Previous irradiation of the oligometastatic site using a dose > 20 Gy less than 5 years ago, 13.Previous treatment with a cytotoxic agent for PCa, 14.Treatment during the past month with products known to influence PSA levels (e.g. fluconazole, finasteride, corticosteroids...), 14. Participation in another clinical study with an investigational product during the last 4 weeks, 16.Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study, 17.Any prior immune therapy (CTLA-4, PD1 or PD-L1 inhibitor, including durvalumab), 18.Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab,. The following are exceptions to this criterion: ?Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) ?Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent ?Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication), 19.Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug, 2. Vertebral metastases with a minimum distance inferior to 5 mm between GTV and spinal cord, 20.Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of Durvalumab., 21.History of allogenic organ transplantation, 22.Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion: ?Patients with vitiligo or alopecia ?Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement ?Any chronic skin condition that does not require systemic therapy ?Patients without active disease in the last 5 years may be included but only after consultation with the study physician ?Patients with celiac disease controlled by diet alone, 23.Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, 24.History of another primary malignancy except for ?Malignancy treated with curative intent and with no known active disease =5 years before the first dose of IP and of low potential risk for recurrence ?Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease ?Adequately treated carcinoma in situ without evidence of disease, 25.History of leptomeningeal carcinomatosis, 26.History of active primary immunodeficiency, 27.Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV
研究者
相似试验
进行中（未招募）
1 期
A phase 2 trial for patients with metastatic prostate cancer to study treatment with nivolumab and ipilimumab with or without radiotherapymetastatic castration-resistant prostate cancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036920Term: Prostate cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003461-34-DKDepartment of Oncology, Herlev & Gentofte Hospital90
招募中
不适用
Phase II multicenter study of Stereotactic Body Radiation Therapy for Hepatocellular CarcinomaNeoplasmsKCT0000422Korea Institute of Radiological & Medical Sciences71
已完成
3 期
A randomized controlled trial of stereotactic body radiation therapy (SBRT) with radiofrequency ablation (RFA) for small hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000002488Department of Gastroenterology, National Hospital Organization, Kyoto Medical Center288
已完成
1 期
A phase I clinical trial of stereotactic body radiotherapy for patients with cervical cancer unsuitable for intracavitary brachytherapyCervical cancerJPRN-UMIN000020519Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital12
已完成
2 期
Prospective phase II study of stereotactic body radiation therapy using helical tomotherapy for stage IA non-small cell lung cancer.stage IA non-small cell lung cancerJPRN-UMIN000001721Aichi Cancer Center Hospital50